# Decoy Therapeutics Inc.: overview DCOY · Nasdaq · CIK 1615219 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/dcoy.md) · [Financials](/companies/dcoy/financials.md) · [Filings](/companies/dcoy/filings.md) · [Insiders](/companies/dcoy/insiders.md) Latest reported revenue: [$227.6k](/filings/0001193125-26-346852.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-346852). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | [0.0](/filings/0001193125-26-346852.md) | not reported | not reported | not reported | [228](/filings/0001193125-26-346852.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(1155.8%)](/filings/0001193125-26-346852.md) | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(1042.8%)](/filings/0001193125-26-346852.md) | | Diluted EPS | $ per share | [(11.38)](/filings/0001615219-25-000164.md) | not reported | [(240.07)](/filings/0001193125-26-214816.md) | [(81.21)](/filings/0001193125-26-346852.md) | [(1.81)](/filings/0001615219-25-000164.md) | not reported | [(4.18)](/filings/0001193125-26-214816.md) | [(4.46)](/filings/0001193125-26-346852.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.8](/filings/0001615219-23-000030.md) | [0.0](/filings/0001615219-23-000030.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(696.3%)](/filings/0001615219-23-000030.md) | not reported | not reported | not reported | not reported | | Net margin | % | [(693.8%)](/filings/0001615219-23-000030.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(7.72)](/filings/0001615219-23-000030.md) | [(14.88)](/filings/0001615219-24-000025.md) | [(30.74)](/filings/0001615219-25-000037.md) | [(69.54)](/filings/0001193125-26-134897.md) | [(129.10)](/filings/0001193125-26-134897.md) | | Free cash flow | $m | [(10.2)](/filings/0001615219-23-000030.md) | not reported | not reported | [(4.5)](/filings/0001193125-26-134897.md) | [(5.4)](/filings/0001193125-26-134897.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dcoy/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $29.0k | 4,034 | | New +4,034 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $1.8k | 256 | | Reduced −765 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $180 | 25 | | Reduced −521 | | [Caitong International Asset Management Co., Ltd](/funds/1963355.md) | 2026-06-30 | $14 | 2 | | New +2 | ## Recent filings [All 743 filings](/companies/dcoy/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-07 | 20:59 ET | [S-1](/filings/0001193125-26-417053.md) | Registration statement | 0001193125-26-417053 | | 2026-09-23 | 21:02 ET | [8-K](/filings/0001615219-26-000019.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001615219-26-000019 | | 2026-09-15 | 21:00 ET | [8-K](/filings/0001615219-26-000016.md) | 5.07 Shareholder vote results | 0001615219-26-000016 | | 2026-08-12 | 20:09 ET | [10-Q](/filings/0001193125-26-346852.md) | Quarterly report, period 2026-06-30 | 0001193125-26-346852 | | 2026-08-04 | 20:59 ET | [DEF 14A](/filings/0001193125-26-332762.md) | Proxy statement, period 2026-09-14 | 0001193125-26-332762 | | 2026-07-15 | 21:14 ET | [8-K](/filings/0001193125-26-304949.md) | 5.07 Shareholder vote results | 0001193125-26-304949 | | 2026-07-10 | 20:26 ET | [S-1](/filings/0001193125-26-300954.md) | Registration statement | 0001193125-26-300954 | | 2026-06-29 | 10:03 ET | [8-K](/filings/0001193125-26-286737.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-286737 | | 2026-06-15 | 22:54 ET | [S-1](/filings/0001193125-26-269891.md) | Registration statement | 0001193125-26-269891 | | 2026-06-04 | 12:26 ET | [DEF 14A](/filings/0001193125-26-256541.md) | Proxy statement, period 2026-06-04 | 0001193125-26-256541 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-134897.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f41093ac-c6eb-4043-9fec-20ddcb43e404) ## About the filer - CIK: 1615219 - Tickers: DCOY - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.